Plant ID: NPO17752
Plant Latin Name: Mentha x piperita
Taxonomy Genus: Mentha
Taxonomy Family: Lamiaceae
NCBI TaxonomyDB:
34256
Plant-of-the-World-Online:
n.a.
Brazil; Italy; Indonesia; India; Jordan; Switzerland
ADORA3; ADORA2A; ADORA1; GPR35; | |
RECQL; TDP1; ADK; PKM; HPGD; AKR1B1; APEX1; POLB; | |
TEK; MET; INSR; EGFR; NUAK1; SRC; KDR; IGF1R; CSNK2A1; | |
CA2; CA14; | |
MMP9; MMP1; MMP2; | |
NFKB1; | |
SLC22A6; | |
SMAD3; LMNA; HSPA1A; | |
SMN1;SMN2; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 8.832E-10 | 1.282E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.545E-08 | 1.051E-05 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.547E-07 | 6.239E-05 | ADORA2A, CSNK2A1, EGFR, HPGD, IGF1R, KDR, MET, MMP9, NFKB1, PKM, SLC22A6, SMAD3, SMN1, SMN2 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.583E-07 | 6.266E-05 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.262E-07 | 8.412E-05 | ADORA2A, APEX1, CA2, CSNK2A1, EGFR, HPGD, NFKB1, SLC22A6, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.279E-07 | 8.412E-05 | ADORA1, LMNA, MMP2, PKM, SMAD3, SRC, TEK |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.790E-07 | 1.196E-04 | ADORA1, ADORA2A, ADORA3 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.790E-07 | 1.196E-04 | EGFR, INSR, KDR |
MF | GO:0005488; binding | GO:0005524; ATP binding | 3.890E-07 | 1.210E-04 | ADK, CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PKM, RECQL, SRC, TEK |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 4.144E-07 | 1.253E-04 | ADORA1, APEX1, CSNK2A1, EGFR, IGF1R, INSR, KDR, MMP9, PKM, SMAD3, SRC |
MF | Unclassified; | GO:0032403; protein complex binding | 5.155E-07 | 1.517E-04 | ADORA1, APEX1, EGFR, IGF1R, INSR, KDR, MMP9, PKM, SMAD3, SRC |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.561E-07 | 1.809E-04 | ADORA1, CA2, EGFR, HPGD, SLC22A6, TEK |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.043E-06 | 2.672E-04 | AKR1B1, APEX1, EGFR, MMP9, SRC |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.424E-06 | 3.563E-04 | ADORA1, ADORA2A, NFKB1, SMAD3, TEK |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 2.608E-06 | 5.933E-04 | EGFR, IGF1R, INSR, KDR, TEK |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.830E-06 | 6.289E-04 | APEX1, POLB |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 5.612E-06 | 1.029E-03 | EGFR, INSR, MET, SRC, TEK |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 6.843E-06 | 1.211E-03 | HPGD, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 7.300E-06 | 1.262E-03 | AKR1B1, APEX1, EGFR, KDR, NFKB1, SRC |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 8.482E-06 | 1.410E-03 | ADORA1, ADORA2A |
BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 9.486E-06 | 1.519E-03 | ADORA1, AKR1B1, APEX1, CA2, EGFR, GPR35, INSR, MET, POLB, SMAD3, SRC |
MF | GO:0005488; binding | GO:0042562; hormone binding | 1.296E-05 | 1.933E-03 | EGFR, IGF1R, INSR, PKM |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.562E-05 | 3.304E-03 | ADORA1, ADORA2A, CA2, KDR, SRC |
BP | GO:0032501; multicellular organismal process | GO:0001889; liver development | 2.988E-05 | 3.642E-03 | CSNK2A1, EGFR, PKM, SMAD3 |
MF | GO:0005488; binding | GO:0031072; heat shock protein binding | 2.988E-05 | 3.642E-03 | ADORA1, CSNK2A1, HSPA1A, KDR |
MF | Unclassified; | GO:0004872; receptor activity | 3.261E-05 | 3.881E-03 | ADORA1, ADORA2A, ADORA3, EGFR, GPR35, HPGD, IGF1R, INSR, KDR, MET, TEK |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 4.126E-05 | 4.631E-03 | EGFR, MMP2, MMP9, TEK |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 4.633E-05 | 5.044E-03 | EGFR, INSR, SMAD3 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.866E-05 | 5.245E-03 | ADK, AKR1B1, APEX1, CSNK2A1, HPGD, HSPA1A, LMNA, NFKB1, NUAK1, POLB, RECQL, SMAD3, SMN1, SMN2, SRC |
BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 5.043E-05 | 5.409E-03 | AKR1B1, APEX1, KDR, NFKB1 |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 5.596E-05 | 5.876E-03 | EGFR, INSR, KDR, SMAD3, SRC |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 5.912E-05 | 6.073E-03 | EGFR, POLB |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 8.078E-05 | 7.966E-03 | ADORA1, ADORA2A, ADORA3, GPR35, IGF1R, INSR, KDR, MET, SLC22A6, TEK |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.011E-04 | 9.533E-03 | ADORA2A, EGFR |
CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 1.011E-04 | 9.533E-03 | ADORA1, ADORA2A |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.808E-11 | 3.874E-09 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.488E-09 | 1.026E-07 | ADORA2A, SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.398E-09 | 2.943E-07 | MMP1, SRC, MMP2, MMP9, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.418E-08 | 1.179E-06 | SRC, MMP2, KDR, MMP9, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.352E-08 | 2.029E-06 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.020E-07 | 3.982E-06 | SMAD3, MMP1, MMP2, MET, MMP9, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 1.805E-07 | 3.982E-06 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.149E-06 | 1.586E-05 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 5.707E-07 | 9.844E-06 | SRC, MMP2, MMP9, EGFR, HSPA1A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 6.952E-07 | 1.066E-05 | INSR, TEK, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 4.642E-06 | 5.824E-05 | SRC, MET, EGFR, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.886E-05 | 2.002E-04 | SRC, KDR, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.081E-05 | 1.243E-04 | HPGD, MMP9, MET, NFKB1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 9.458E-05 | 8.702E-04 | SMAD3, SRC, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 6.585E-05 | 6.491E-04 | SMAD3, INSR, EGFR, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.592E-04 | 1.373E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.745E-04 | 1.399E-03 | SMAD3, EGFR, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 3.475E-04 | 2.323E-03 | POLB, PKM, SRC, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.167E-04 | 1.574E-03 | MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.824E-04 | 1.399E-03 | PKM, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 4.219E-04 | 2.647E-03 | EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 6.109E-04 | 3.372E-03 | SMAD3, MMP2, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 4.504E-04 | 2.702E-03 | SRC, MMP2, EGFR |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 4.953E-04 | 2.848E-03 | INSR, NFKB1, IGF1R |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.074E-03 | 5.488E-03 | ADORA2A, GPR35, ADORA3, ADORA1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.389E-03 | 6.609E-03 | MMP9, MET, EGFR, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.008E-03 | 5.349E-03 | ADORA3, ADORA1, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.445E-03 | 6.648E-03 | CSNK2A1, NFKB1, HSPA1A |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.350E-03 | 6.609E-03 | POLB, APEX1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.535E-04 | 2.323E-03 | CA2, CA14 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; INSR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; MMP1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; MMP9; EGFR; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; |
NA: NA | Edema | NA | CA2; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; NFKB1; ADORA3; TEK; MMP9; EGFR; SRC; MMP2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
C00-D49: Neoplasms | AML | NA | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; MMP9; EGFR; SRC; PKM; MMP2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; TEK; SRC; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; MMP2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; ADORA2A; INSR; ADK; PKM; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; INSR; AKR1B1; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; INSR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |